Controlled release ion channel modulator compositions and methods for the treatment of otic disorders

A method of treating otic disorders selected from the group consisting of Meniere's Disease, endolymphatic hydrops, progressive hearing loss, dizziness, vertigo and tinnitus in an individual in need thereof comprising intratympanic administration of a sterile pharmaceutical composition into the ear, the composition comprising:

• an auris acceptable thermoreversible aqueous gel having a gelation viscosity between about 15,000 cP and about 1,000,000 cP comprising of a copolymer of polyoxyproplene and polyoxyethylene and a multiparticle ion channel modulating agent selected from linopirdine;
• XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone);
• 4-AP (4-aminopyridine);
• 3,4-DAP (3,4-Diaminopyridine);
• E-4031 (4′-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidinyl]carbonyl]-methanesulfonanilide);
• DIDS (4,4′-diisothiocyanostilbene-2,2′-disulfonic acid);
• Way 123,398 (N-methyl-N-(2-(methyl(1-methyl-1H-benzimidazol-2-yl)amino)ethyl)-4-((methylsulfonyl)amino) benzenesulfonamide HCl);
• CGS-12066A (7-Trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline);
• dofetilide;
• sotalol;
• apamin;
• amiodarone;
• azimilide;
• bretylium;
• clofilium;
• tedisamil;
• ibutilide;
• sematilide;
• nifekalant;
• and tamulustoxin,
• such that sustained release of the ion channel modulating agent into the ear occurs for a period of at least 3 days.